Ischemia Reperfusion Injury Therapeutics Market

Ischemia Reperfusion Injury Therapeutics Market (Treatment: Drug Therapy, Medicated Gases, and Others: Injury Type: Heart Injury, Kidney Injury, Intestine Injury, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Ischemia Reperfusion Injury Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 2.3 Bn in 2021
  • It is projected to grow at a CAGR of 3.5% from 2022 to 2031 and reach more than US$ 3.2 Bn by the end of 2031

Analysts’ Viewpoint

The global ischemia reperfusion injury therapeutics market is driven by rise in prevalence of cardiovascular diseases, increase in geriatric population, and surge in awareness about ischemia reperfusion injuries among healthcare professionals and patients. Advancements in technology and development of new and effective therapies present significant opportunities for manufacturers in the market. Furthermore, government initiatives and funding for research & development of new therapies support market development.

The COVID-19 pandemic led to a decrease in the number of elective surgeries, leading to a decline in number of cases of ischemia reperfusion injury. Additionally, the pandemic led to a decrease in funding for research & development. However, surge in focus on COVID-19 treatments contributed to new discoveries and advancements that could benefit the treatment of ischemia reperfusion injury in future.

Ischemia Reperfusion Injury Therapeutics Market

Ischemia Reperfusion Injury Therapeutics Market Introduction

Ischemia-reperfusion injury (IRI) occurs when blood flow to an area of tissue is blocked (ischemia) and subsequently restored (reperfusion). This could happen during situations, such as heart attack, stroke, or surgery, where a blood vessel is temporarily blocked and then reopened. During ischemia, the tissue is deprived of oxygen and nutrients, which could cause damage to cells and tissues. When blood flow is restored (reperfusion), the sudden influx of oxygen can cause a cascade of harmful reactions, including inflammation and the generation of reactive oxygen species (ROS), leading to further damage to the tissue. This injury could lead to functional and structural impairments of the organ, such as myocardial infarction, stroke, and kidney injury.

A rise in a number of patients requiring treatment for IRI due to an increase in the incidence of cardiovascular diseases and organ transplants is driving market expansion. The surge in healthcare expenditure and rise in awareness about IRI and its treatment options are propelling market progress.

Development of new drugs and therapies that can effectively target and treat IRI and expansion of existing treatments into new indications are augmenting the market. Increase in incidence of IRI-related conditions, such as heart attack and stroke, is expected to bolster global ischemia reperfusion injury therapeutics market growth. Development of new diagnostic tools and increase in usage of telemedicine and other digital technologies to improve patient outcomes present significant opportunities for companies in the industry.

Rise in Prevalence of Cardiovascular Diseases

Increase in patient population in need of IRI treatment due to rise in prevalence of cardiovascular diseases, such as heart attack and stroke, is driving ischemia-reperfusion injury therapeutics market share. The ischemia-reperfusion injury could occur during certain medical procedures, such as angioplasty, and is a leading cause of tissue damage in patients with cardiovascular disease. Ischemia-reperfusion injury therapeutics market demand is expected to be driven by aging population and increase in risk factors for cardiovascular diseases, such as obesity and diabetes.

Cardiovascular diseases (CVDs) is a leading cause of death across the world. According to the World Health Organization (WHO), CVDs are a major cause of death globally, accounting for 17.9 million deaths per year. Prevalence of CVDs is increasing due to aging population and surge in risk factors such as obesity and diabetes. Additionally, CVDs are more common in low- and middle-income countries, where access to healthcare and preventative measures is limited.

Increase in Awareness about Diseases among Healthcare Professionals and Patients

Surge in awareness about IRI among healthcare professionals and patients is driving the demand for effective treatments. Awareness among healthcare professionals about this condition is rising due to education and training. This, in turn, is likely to increase diagnosis and treatment. Patients are more informed about the condition and its potential complications. Surge in awareness about IRI is leading to rise in research & development and introduction of a number of products to treat the condition.

Awareness about IRI is rising due to increase in research and understanding of the mechanisms involved and the potential interventions that could be used to mitigate its effects. Additionally, usage of ischemia reperfusion in various clinical settings, such as organ transplantation and cardiopulmonary bypass surgery, has led to increase in attention and awareness about the condition. Furthermore, growing interest in regenerative medicine has led to increase in focus on the role of ischemia reperfusion in tissue injury and repair. Therefore, rise in awareness among healthcare professionals and patients is projected to drive the demand for ischemia reperfusion injury therapeutics during the forecast period.

Development of New and Effective Therapies

Development of new and effective therapies for IRI that are more effective and have fewer side effects than current therapies is expected to bolster ischemia reperfusion injury therapeutics market growth. This is likely to lead to increase in demand for these therapies and rise in revenue of companies. Additionally, ongoing research and development in IRI therapeutics could lead to discovery of new targets and mechanisms for therapy. This, in turn, is projected to accelerate market growth.

Development of new and effective therapies, such as drugs that can target specific pathways or molecules involved in the injury process, in anticipated to propel the industry. For instance, drugs that inhibit inflammation or oxidative stress could help reduce tissue damage caused by IRI.

Usage of regenerative medicine techniques, such as stem cell therapy, to repair or replace damaged cells and tissues could lead to the development of therapies that can help restore function to the affected area and reduce the risk of complications. Additionally, new technologies, such as remote monitoring and telemedicine, are being used to improve the diagnosis and treatment of IRI.

Recent developments in new therapies for IRI include usage of stem cells and exosomes, pharmacological agents such as statins and phosphodiesterase inhibitors, and utilization of remote ischemic preconditioning. Other promising areas of research are usage of hyperbaric oxygen therapy and utilization of extracorporeal devices to remove damaging molecules from the blood.

Widely Accepted Treatment Option

In terms of treatment, the drug therapy segment dominated the global ischemia reperfusion injury therapeutics market in 2021. Drugs are widely accepted and established form of treatment for IRIs. These drugs, which target inflammation or oxidative stress, could effectively reduce the damage caused by IRIs and improve patient outcomes. Additionally, development of new and more effective drugs for treating IRI is ongoing. This is expected to drive the drug therapy segment in the next few years.

Rise in Heart Attacks Globally

Based on injury type, the heart injury segment accounted for the largest share of the global market in 2021. Heart injury is a common type of IRI. Heart attack is a leading cause of death and disability across the world. Furthermore, advances in medical technology, such as development of new drugs and procedures for treating heart attacks, is projected to augment the heart injury segment.

Regional Outlook of Global Ischemia Reperfusion Injury Therapeutics Market

North America dominated the global ischemia reperfusion injury therapeutics industry in 2021. Incidence of IRI is high in the region due to significant prevalence of cardiovascular diseases and large number of surgeries performed. Additionally, well-established healthcare infrastructure enables early diagnosis and treatment of IRI in North America. Governments in the region support the development and promotion of new treatments for IRI through funding and incentives for research & development. High healthcare expenditure also contributes to the growth of the market in North America, as patients have access to advanced treatments and technologies.

The market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. This is ascribed to increase in geriatric population, which is more susceptible to IRI, and rise in awareness among healthcare professionals and general public. Expanding healthcare infrastructure and increase in availability of advanced medical technologies contribute to market growth in the region. Furthermore, rise in number of surgical procedures and increase in focus on organ transplantation drive the market in Asia Pacific.

Analysis of Key Players

This report provides profiles of leading players operating in the global ischemia reperfusion injury therapeutics market. These include Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., SBI Pharmaceuticals, Faraday Pharmaceuticals, and Zealand Pharma A/S. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand market presence.

Key Developments in Global Ischemia Reperfusion Injury Therapeutics Market

  • In March 2022, SBI Pharmaceuticals and the University of Oxford announced that the former initiated a phase II clinical trial to develop a cardioprotective agent combining 5-ALA hydrochloride and sodium ferrous citrate for the mitigation of IRI in response to cardiac surgery under cardiopulmonary bypass. The trial is sponsored by both parties under the clinical trial sponsorship agreement.
  • In November 2019, Faraday Pharmaceuticals announced progressive results from the phase II clinical trials of FDY-5301. It is a sodium iodide containing, formulated, patented, elemental reducing agent. It works by destroying hydrogen peroxide, which is naturally produced as a response to acute ischemia reperfusion injury and contributes to muscle function and mass loss. The drug is being developed to treat ischemia reperfusion injury caused by a STEMI heart attack.

Leading players have been profiled in the report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Ischemia Reperfusion Injury Therapeutics Market Snapshot

Attribute

Detail

Size in 2021

US$ 2.3 Bn

Forecast (Value) in 2031

More than US$ 3.2 Bn

Growth Rate (CAGR) 2022-2031

3.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Treatment
    • Drug Therapy
    • Medicated Gases
    • Others
  • Injury Type
    • Heart Injury
    • Kidney Injury
    • Intestine Injury
    • Others
  • End-user
    • Hospitals
    • Specialty Clinics
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amyndas Pharmaceuticals LLC
  • Angion
  • Bolder Biotechnology
  • Opsona Therapeutics Ltd.
  • Pharming Group NV
  • Prolong Pharmaceuticals
  • Prothix BV
  • Stealth BioTherapeutics, Inc.
  • Zealand Pharma A/S
  • Faraday Pharmaceuticals
  • SBI Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global ischemia reperfusion injury therapeutics market in 2021?

The global market was valued at US$ 2.3 Bn in 2021

How big will it be in 2031?

It is projected to reach more than US$ 3.2 Bn by 2031

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 3.5% from 2022 to 2031

Which segment held major share?

The drug therapy segment accounted for significant share in 2021

Which region will account for leading share?

North America is expected to account for the largest share during the forecast period.

Who are the prominent players in the market?

Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Faraday Pharmaceuticals, SBI Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc., and Zealand Pharma A/S.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Ischemia Reperfusion Injury Therapeutics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Development

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Disease Epidemiology

        5.2. Pipeline Analysis

        5.3. COVID 19 Impact on Industry

    6. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Treatment

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Treatment, 2017–2031

            6.3.1. Drug Therapy

            6.3.2. Medicated Gases

            6.3.3. Others

        6.4. Market Attractiveness Analysis, by Treatment

    7. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Injury Type

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Injury Type, 2017–2031

            7.3.1. Heart Injury

            7.3.2. Kidney Injury

            7.3.3. Intestine Injury

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by Injury Type

    8. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Specialty Clinics

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by End-user

    9. Global Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment, 2017–2031

            10.2.1. Drug Therapy

            10.2.2. Medicated Gases

            10.2.3. Others

        10.3. Market Value Forecast, by Injury Type, 2017–2031

            10.3.1. Heart Injury

            10.3.2. Kidney Injury

            10.3.3. Intestine Injury

            10.3.4. Others

        10.4. Market Value Forecast, by End-user, 2017–2031

            10.4.1. Hospitals

            10.4.2. Specialty Clinics

            10.4.3. Others

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Treatment

            10.6.2. By Injury Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment, 2017–2031

            11.2.1. Drug Therapy

            11.2.2. Medicated Gases

            11.2.3. Others

        11.3. Market Value Forecast, by Injury Type, 2017–2031

            11.3.1. Heart Injury

            11.3.2. Kidney Injury

            11.3.3. Intestine Injury

            11.3.4. Others

        11.4. Market Value Forecast, by End-user, 2017–2031

            11.4.1. Hospitals

            11.4.2. Specialty Clinics

            11.4.3. Others

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Treatment

            11.6.2. By Injury Type

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment, 2017–2031

            12.2.1. Drug Therapy

            12.2.2. Medicated Gases

            12.2.3. Others

        12.3. Market Value Forecast, by Injury Type, 2017–2031

            12.3.1. Heart Injury

            12.3.2. Kidney Injury

            12.3.3. Intestine Injury

            12.3.4. Others

        12.4. Market Value Forecast, by End-user, 2017–2031

            12.4.1. Hospitals

            12.4.2. Specialty Clinics

            12.4.3. Others

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Treatment

            12.6.2. By Injury Type

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment, 2017–2031

            13.2.1. Drug Therapy

            13.2.2. Medicated Gases

            13.2.3. Others

        13.3. Market Value Forecast, by Injury Type, 2017–2031

            13.3.1. Heart Injury

            13.3.2. Kidney Injury

            13.3.3. Intestine Injury

            13.3.4. Others

        13.4. Market Value Forecast, by End-user, 2017–2031

            13.4.1. Hospitals

            13.4.2. Specialty Clinics

            13.4.3. Others

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Treatment

            13.6.2. By Injury Type

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment, 2017–2031

            14.2.1. Drug Therapy

            14.2.2. Medicated Gases

            14.2.3. Others

        14.3. Market Value Forecast, by Injury Type, 2017–2031

            14.3.1. Heart Injury

            14.3.2. Kidney Injury

            14.3.3. Intestine Injury

            14.3.4. Others

        14.4. Market Value Forecast, by End-user, 2017–2031

            14.4.1. Hospitals

            14.4.2. Specialty Clinics

            14.4.3. Others

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Treatment

            14.6.2. By Injury Type

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Amyndas Pharmaceuticals LLC

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Portfolio

                15.3.1.3. Financial Overview

                15.3.1.4. SWOT Analysis

                15.3.1.5. Strategic Overview

            15.3.2. Angion

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Portfolio

                15.3.2.3. Financial Overview

                15.3.2.4. SWOT Analysis

                15.3.2.5. Strategic Overview

            15.3.3. Bolder Biotechnology

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Portfolio

                15.3.3.3. Financial Overview

                15.3.3.4. SWOT Analysis

                15.3.3.5. Strategic Overview

            15.3.4. Opsona Therapeutics Ltd.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Portfolio

                15.3.4.3. Financial Overview

                15.3.4.4. SWOT Analysis

                15.3.4.5. Strategic Overview

            15.3.5. Pharming Group NV

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Portfolio

                15.3.5.3. Financial Overview

                15.3.5.4. SWOT Analysis

                15.3.5.5. Strategic Overview

            15.3.6. Prolong Pharmaceuticals

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Portfolio

                15.3.6.3. Financial Overview

                15.3.6.4. SWOT Analysis

                15.3.6.5. Strategic Overview

            15.3.7. Prothix BV

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Portfolio

                15.3.7.3. Financial Overview

                15.3.7.4. SWOT Analysis

                15.3.7.5. Strategic Overview

            15.3.8. Stealth BioTherapeutics, Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Portfolio

                15.3.8.3. Financial Overview

                15.3.8.4. SWOT Analysis

                15.3.8.5. Strategic Overview

            15.3.9. Zealand Pharma A/S

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Portfolio

                15.3.9.3. Financial Overview

                15.3.9.4. SWOT Analysis

            15.3.10. Faraday Pharmaceuticals

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Portfolio

                15.3.10.3. Financial Overview

                15.3.10.4. SWOT Analysis

            15.3.11. SBI Pharmaceuticals

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Portfolio

                15.3.11.3. Financial Overview

                15.3.11.4. SWOT Analysis

                15.3.11.5. Strategic Overview

    List of Tables

    Table 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 02: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 03: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 06: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 07: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 08: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 09: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 10: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 11: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 14: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 15: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 16: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 18: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 19: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 20: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 21: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 22: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Injury Type, 2017–2031

    Table 23: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 24: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 03: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 04: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 05: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 06: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 07: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 08: Global Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Region, 2021 and 2031

    Figure 09: Global Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

    Figure 10: North America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 12: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 13: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 14: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 15: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 16: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 17: North America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country, 2021 and 2031

    Figure 18: North America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

    Figure 19: Europe Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 20: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 21: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 22: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 23: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 24: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 25: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 26: Europe Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 27: Europe Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 28: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 29: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 30: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 31: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 32: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 33: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 34: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 35: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 36: Asia Pacific Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 37: Latin America Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 38: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 39: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 40: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 41: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 42: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 43: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 44: Latin America Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 45: Latin America Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 46: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 47: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Treatment, 2021 and 2031

    Figure 48: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Treatment, 2022–2031

    Figure 49: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Injury Type, 2021 and 2031

    Figure 50: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Injury Type, 2022–2031

    Figure 51: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by End-user, 2021 and 2031

    Figure 52: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 53: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 54: Middle East & Africa Ischemia Reperfusion Injury Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 55: Global Ischemia Reperfusion Injury Therapeutics Market Share Analysis, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved